Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
November 2012, Vol 3, No 8
November 2012, Vol 3, No 8
Cost-Effectiveness Comparison of First-Line Therapies for Advanced Non–Small-Cell Lung Cancer
By
Caroline Helwick
ESMO 2012 Conference
,
ESMO
November 2012, Vol 3, No 8
Vienna, Austria—Costs associated with first-line pemetrexed/cisplatin are significantly lower than those of carboplatin/paclitaxel/bevacizumab for the treatment of advanced non–small-cell lung cancer (NSCLC), according to an analysis presented at the 2012 European Society for Medical Oncology Congress.
Read Article
Platinum-Resistant Ovarian Cancer: Bevacizumab Improves Survival When Added to Chemotherapy
By
Phoebe Starr
ESMO 2012 Conference
,
ESMO
November 2012, Vol 3, No 8
Vienna, Austria—Adding bevacizumab (Avastin) to chemotherapy improves outcomes in patients with platinum-resistant recurrent ovarian cancer, according to results of the phase 3 clinical trial AURELIA, which was presented at the 2012 European Society for Medical Oncology Congress.
Read Article
To Many Employers, Specialty Pharmacy Is a Vague Concept
By
Caroline Helwick
Specialty Pharmacy
November 2012, Vol 3, No 8
Houston, TX—Most employers do not understand biologics and specialty pharmacy well enough to use services appropriately and to take advantage of their benefits, said F. Randy Vogenberg, RPh, PhD, Principal, Institute for Integrated Healthcare, Sharon, MA, an employer benefit consulting company.
Read Article
Employers’ Challenge: Cut Healthcare Costs Without Limiting Employees’ Benefits
By
Caroline Helwick
November 2012, Vol 3, No 8
Houston, TX—Employers’ health plan managers must “balance members’ access to new treatments with the fiscal responsibility of managing the healthcare financial resources wisely,” said Bridget Eber, PharmD, Senior Consultant and Clinical Lead of Rx Group Purchasing, Towers Watson, at the 2012 Second Annual Association for Value-Based Cancer Care Conference.
Read Article
No Increase in Leukemia or MDS with Adjuvant Chemotherapy for Breast Cancer
By
Audrey Andrews
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—According to a study from the US Oncology Network, patients with breast cancer who are treated with adjuvant chemotherapy have no increased risk for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), at least within the first 3 years of treatment.
Read Article
Costly Acute Care Episodes Are Common for Patients with Early Breast Cancer
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—Acute care utilization, namely, emergency department visits and hospitalizations, are surprisingly common among patients with early breast cancer, according to a retrospective study using an administrative database in Ontario, Canada.
Read Article
Some Staging Studies Not Beneficial in Early Breast Cancer Work-Up
By
Caroline Helwick
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—Three frequently used radiologic tests rarely detect metastases in patients with a new diagnosis of breast cancer and should not be routinely performed, according to a comprehensive literature review presented at the 2012 Breast Cancer Symposium.
Read Article
Newer, More Costly Radiation Technologies Adopted in Elderly Patients with Breast Cancer
By
Phoebe Starr
ASTRO Annual Meeting
November 2012, Vol 3, No 8
In a study of patients who were enrolled in the Surveillance, Epidemiology and End Results–Medicare database, these utilization patterns led to a cost increase of 63% per patient. The study’s results were reported at the 2012 American Society for Radiation Oncology annual meeting.
Read Article
Abraxane Receives New Indication for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer, in Combination with Carboplatin, in Patients Who Are Not Candidates for Curative Surgery or Radiation Therapy
By
Lynne Lederman, PhD, Medical Writer
Drug Updates
November 2012, Vol 3, No 8
Read Article
CMS Finalizes Payment Policies for 2013, Signaling a Shift toward Paying for Value
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
November 2012, Vol 3, No 8
In this article we address the final payment rules issued on November 1, 2012, by the Centers for Medicare & Medicaid Services (CMS), the Physician Fee Schedule (PFS), and the Hospital Outpatient Prospective Payment System.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma